Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Interview with the Innovators
Lung Cancer, ASCO Highlights
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Read More
Lung Cancer
2021 Midyear Review: Non–Small-Cell Lung Cancer
Read More
Case Report, Lung Cancer
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer
Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP
Read More
FDA Updates, Lung Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
Read More
FDA Updates, Lung Cancer
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
Read More
FDA Updates, Lung Cancer
Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
Read More
Lung Cancer
GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC
Read More
Lung Cancer
Ramucirumab plus Erlotinib in the Treatment of Patients with NSCLC with EGFR Exon 19 or Exon 21 Mutations
Read More
Lung Cancer
First-Line Treatment with Lorlatinib Improves Outcomes Over Crizotinib in Patients with ALK-Positive NSCLC
Read More
Page 1 of 9
Results 1 - 10 of 84
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.